Serum Fetuin Level in Polycystic Ovary Syndrome

Polycystic Ovary Clinical Trial

Official title:

Serum Fetuin Level as a Marker in Polycystic Ovary Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03819998
• Other study ID #: Fetuin
• Status: Recruiting
• Start date: January 30, 2019
• Est. completion date: February 5, 2020

Study information

• Verified date: August 2019
• Source: Aljazeera Hospital
• Contact: Mahmoud Alalfy, PhD
• Phone: 01002611058
• Email: mahmoudalalfy[@]ymail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

polycystic ovary syndrome is a common gynecological problem

Description:

Understanding the pathophysiology and the cause is of much importance for proper management of this problem

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: February 5, 2020
• Est. primary completion date: February 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 42 Years

Eligibility

Inclusion Criteria:

• women who have PCOS in group 1 and who donnot have PCOS in group 2 with age between 20 -42 years

Exclusion Criteria:

• women above 42 years old

Related Conditions & MeSH terms

• Polycystic Ovary
• Polycystic Ovary Syndrome

Intervention

Diagnostic Test:
• measurement of Fetuin-A level in serum
Fetuin A level will be measured in blood of the PCOS women

Locations

Country	Name	City	State
Egypt	Algazeerah and Kasralainy hospital	Giza

Sponsors (3)

Lead Sponsor	Collaborator
Aljazeera Hospital	Cairo University, National Research Center, Egypt

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of women who will have high level of fetuin A and has PCOS	Evaluation of women who have PCOS in relation to fetuin A level	within a week